Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL

Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

Correlative findings from the phase 2 ZUMA-2 trial demonstrated that the pharmacokinetic and pharmacodynamic profiles of KTE-X19 were generally comparable across lower and high-risk patients, leading to similar clinical responses. Additionally, the data showed that cytokines can predict the depth of response and neurologic toxicity of the therapy, says Wang. For example, 83% of patients achieved minimal residual disease (MRD) negativity 1 month after receiving KTE-X19. These patients had increased median cytokine levels of interferon (INF)-γ, interleukin (IL)-6, IL-15, IL-2, and IL-10. The serum levels peaked within 7 days of treatment.

Moreover, 6 patients developed grade 4 neurologic events, including 1 case of cerebral edema. Three of these patients developed concurrent grade 4 cytokine release syndrome. Notably, this subgroup of patients had higher peak serum levels of INF-γ, tumor necrosis factor alpha, monocyte chemoattractant protein-1, IL-2 and IL-6 than patients without any grade 4 neurologic events.

<<< 2020 ASCO Virtual Scientific Program

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD